 |
 |

Dextromethorphan Challenge in Alcohol-Dependent Patients and Controls
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In a recent article, Krystal et al1 demonstrated dose-dependent ethanol-like effects in detoxified alcoholic patients induced by ketamine, a high-affinity noncompetitive N-methyl-D-aspartate (NMDA) antagonist. Alcohol has repeatedly been shown to have NMDA antagonistic effects2; however, whether it resembles high-affinity or low-affinity NMDA is not clear. Preclinical drug discrimination studies have shown dextromethorphan, a low-affinity noncompetitive NMDA antagonist, to have effects that overlap with, but do not fully resemble, ketamine.3 Like ketamine, dextromethorphan is not a pure NMDA antagonist, especially since binding has been reported.4 The properties of receptors and nonopioid non-NMDA receptors are not well understood.
Dextromethorphan has been used as an over-the-counter antitussive medication for more than 40 years. Its safety profile is extremely favorable. Recently, it has received renewed interest as a medication with neuroprotective effects.5 Other areas of ongoing research include treatment of opioid-dependent patients and use as a tolerance-decreasing adjuvant medication in pain treatment.6 . . . [Full Text of this Article]
|